

# Global Attention Deficit Hyperactivity Disorder (ADHD) Market Analysis, Trends, Growth, Size Share, 2019

---

PUNE, MAHARASHTRA, INDIA, February 28, 2019 /EINPresswire.com/ -- DelveInsight's Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Attention Deficit Hyperactivity Disorder (ADHD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Attention Deficit Hyperactivity Disorder (ADHD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

## Geography Covered

The United States  
EU5 (Germany, France, Italy, Spain and the United Kingdom)  
Japan

Study Period: 2016-2027

## Attention Deficit Hyperactivity Disorder (ADHD) - Disease Understanding and Treatment Algorithm

According to American Psychiatric Association, Attention Deficit Hyperactivity Disorder (ADHD) is a brain/neurodevelopmental/neurobehavioral disorder and is one of the most common mental disorders affecting children. The disease also affects many adults. Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) include inattention (not being able to keep focus), hyperactivity (excess movement that is not fitting to the setting) and impulsivity (hasty acts that occur in the moment without thought).

According to National Institute of Mental Health, Inattention and hyperactivity/impulsivity are the key behaviors of Attention Deficit Hyperactivity Disorder (ADHD). Some people with Attention Deficit Hyperactivity Disorder (ADHD) only have problems with one of the behaviors, while others have both inattention and hyperactivity-impulsivity. Most children have the combined type of Attention Deficit Hyperactivity Disorder (ADHD). ADHD is diagnosed as one of three types: inattentive type, hyperactive/impulsive type or combined type.

The DelveInsight [Attention Deficit Hyperactivity Disorder \(ADHD\) market](#) report gives the thorough understanding of the ADHD by including details such as disease definition, symptoms,

causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Attention Deficit Hyperactivity Disorder (ADHD) in the US, Europe, and Japan.

## Attention Deficit Hyperactivity Disorder (ADHD) Epidemiology

The Attention Deficit Hyperactivity Disorder (ADHD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalence of Attention Deficit Hyperactivity Disorder (ADHD), Age specific prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD), Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD)] scenario of Attention Deficit Hyperactivity Disorder (ADHD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

According to National Institute of Mental Health, the prevalence of children ever diagnosed with ADHD increased by 42% between 2003 (7.8%) and 2011 (11.0%).

As per National Comorbidity Survey-Adolescent Supplement (NCS-A), the lifetime prevalence of ADHD among U.S. adolescents aged 13 to 18 years was found to be 8.7%.

According to National Resource Center on ADHD, the estimates of worldwide adult ADHD prevalence averaged 3.4%.

According to ADHD Institute, meta-regression analyses have estimated the worldwide ADHD prevalence between 5.29% and 7.1% in children and adolescents, and at 3.4% (range 1.2–7.3%) in adults. The prevalence of Attention-deficit hyperactivity disorder (ADHD) is greater in males (60%) than females (40%).

## Attention Deficit Hyperactivity Disorder (ADHD) Drug Chapters

This segment of the Attention Deficit Hyperactivity Disorder (ADHD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently available treatments can help reduce symptoms and improve functioning. Treatments include medications, psychotherapy, education or training, or a combination of treatments. The specific class of medications most commonly prescribed for Attention Deficit Hyperactivity Disorder (ADHD) include Stimulants. These Stimulant medications are found to be well-tolerated and they act quickly. Stimulant medications commonly prescribed for attention deficit disorder include methylphenidate (Ritalin, Concerta, Metadate, Methylin) and certain amphetamines (Dexedrine, Adderall etc.).

Other newer drugs approved for the treatment of Attention Deficit Disorder include Strattera (Eli Lilly) and Vyvanse (Shire). These drugs typically offer similar benefits to stimulants, but act in a different way on the brain. Antidepressants are also given in some cases. All these ADHD drugs however are related with certain side-effects such as decrease appetite, insomnia and decreased

anxiety. Psychostimulants have also shown to be effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), but, their shorter duration of action highlights potential limitations.

Many players such as Sunovion, Orient Pharma, NeuroDerm and some other are involved in developing therapies for Attention Deficit Hyperactivity Disorder. Launch of emerging therapies such as Dasotraline (Sunovion) and ND0801 (NeuroDerm) etc. are expected to significantly change the treatment landscape of ADHD in the upcoming years.

Table of Contents

Report Introduction

Attention Deficit Hyperactivity Disorder (ADHD) Market Overview at a Glance

2.1. 7 Major Market Size of Attention Deficit Hyperactivity Disorder (ADHD) in 2017

2.2. 7 Major Market Size of Attention Deficit Hyperactivity Disorder (ADHD) in 2027

Disease Background and Overview: Attention Deficit Hyperactivity Disorder (ADHD)

3.1. Introduction

3.2. Causes

3.3. Pathophysiology

3.4. Symptoms

3.5. Risk Factor

3.6. Diagnosis

Epidemiology and Patient Population

4.1. Assumptions and Caveats

4.2. 7MM Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)

4.3. 7MM Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)

4.4. 7MM Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD) (2016-2027)

4.5. Attention Deficit Hyperactivity Disorder (ADHD): Country- Wise Epidemiology

4.6. United States

4.6.1. Assumptions and Rationale

4.6.2. Prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

4.6.3. Age specific prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the United States (2016-2027)

4.6.4. Diagnosed and Treatable Cases of Attention

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.